Leah Hogdal is a Director of Biomarkers for Late-Stage ADC Development at Pfizer, a position they currently hold. They previously served as Associate Director of Clinical Biomarkers at Seagen from 2021 to 2024 and held various research positions, including postdoctoral fellowships at Vanderbilt University and the National Institutes of Health. Leah earned a Ph.D. in Biological Chemistry & Molecular Pharmacology and contributed to cancer research as a graduate student at Dana-Farber Cancer Institute / Harvard University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices